Overview

Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia

Status:
Terminated

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic Leukemia (CLL). 2. To determine the toxicity profile of clofarabine in CLL. 3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology profile of clofarabine in CLL.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Clofarabine